Communiqués PharmaEngine, Inc.

Actions

4162

TW0004162003

Recherche biotechnologique et médicale

Cours en clôture Taipei Exchange Autres places de cotation 11/08/2026			Varia. 5j.	Varia. 1 janv.
63,70 ^TWD	-1,55%		+2,74%	-9,52%

06/08	PharmaEngine, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
12/05	PharmaEngine, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

03/08/22	PharmaEngine : Phase III RESILIENT trial evaluating Onivyde in second-line monotherapy for small cell lung cancer did not meet its primary endpoint	PU
26/07/22	PharmaEngine : to attend 1H22 financial status investor conference hosted by Cathay Securities	PU
26/07/22	PharmaEngine : Announcement on the record date for the capital increase of Employee Restricted Shares and related matters	PU
26/07/22	PharmaEngine : Announcement of the resolution by the company’s board of directors for the ex-dividend record date of cash dividends	PU
26/07/22	PharmaEngine : announces the board resolutions on approving the Second Quarter of 2022 consolidated financial report	PU
27/05/22	PharmaEngine : Announcement of the new chairperson of The Company	PU
27/05/22	PharmaEngine : The Company announced the new-elected members of the Audit Committee	PU
27/05/22	PharmaEngine : The Company announced the new-elected members of the Compensation Committee	PU
27/05/22	PharmaEngine : Important resolutions of the Company's 2022 Annual Shareholders' Meeting	PU
27/05/22	PharmaEngine : Announcement of the 2022 shareholders' meeting resolution of new-elected 9 directors (including 3 independent directors)	PU
28/04/22	PharmaEngine : to attend Cathay Securities Investor Conference hosted by Cathay Securities	PU
28/04/22	PharmaEngine : announces the board resolutions on approving the First Quarter of 2022 consolidated financial report.	PU
18/04/22	PharmaEngine : Clarification of media reporting	PU
15/04/22	PharmaEngine : announced that the China NMPA has granted approval for ONIVYDE Regimen for the Treatment of Metastatic Pancreatic Cancer	PU
08/03/22	PharmaEngine : to attend Yuanta Securities Investor Conference hosted by Yuanta Securities	PU
08/03/22	PharmaEngine : Announcement that the Company's Board of Directors resolved to issue restricted stock awards (RSA)	PU
08/03/22	PharmaEngine : The Company's Board of Directors resolved to convene the 2022 Annual General Shareholders' Meeting (Additional cause for convening the meeting)	PU
08/03/22	PharmaEngine : announces the board resolutions on approving the Full Year of 2021 consolidated financial report.	PU
08/03/22	PharmaEngine : Correction to December 2021 Consolidated Revenue and Full Year 2021 Accumulated Revenue Announcement	PU
01/03/22	PharmaEngine : Announcement of cancellation of the Company treasury shares and change of paid-in capital registration	PU
10/02/22	PharmaEngine : to attend QIC Healthcare Forum hosted by Quantum International CORP.	PU